Multiple Prefilled Syringe Combination Products are Available in the Market
by Roots Analysis Roots Analysis provides market research and consulMultiple Prefilled Syringe Combination Products are Available
in the Market, While Several Are Under Development, for the Treatment of a Variety
of Disease Indications Across the World
Most self-injection devices / systems, such as autoinjectors and pen-injectors, rely on prefilled syringes, which serve as primary drug containers in the aforementioned products. Moreover, despite having been in the market for more than three decades now, the overall interest in prefilled syringes continues to grow. In fact, the recent increase in use of biologics, which are usually administered via parenteral routes, has had a significant impact on the demand for prefilled syringes. This is primarily due to reason that, prefilled syringes have been the container of choice for many biologic molecules, including monoclonal antibodies (mAbs) and vaccines. Some factors responsible for this preference include:
§ Most biologics require parenteral administration
§ Biologics are costlier than pharmaceutical drugs and packaging of
biologics in prefilled syringes reduces overfills, saving costs
§ Prefilled syringes allow product differentiation
§ Ease of use and ability to save time helps to deploy vaccines in
mass immunization programs
§ Ease of use allows self-administration of drugs for chronic
conditions
As
mentioned above, in addition to end-users, prefilled syringes also offer
several advantages to manufacturers. However, some technical issues, such as
functionality issues and syringe siliconization, are yet to be addressed to
ensure better compatibility between the drug and the device. It is worth
highlighting that development of biologics in combination with prefilled
syringes has garnered a lot of interest in the biopharma industry. In the last few years (2013-2019), close to 90 drugs
have been approved in combination with prefilled syringes. Humira®, Rituxan®,
REMICADE®, STELARA®, Enbrel®, GARDASIL® and PREVNAR 13® are examples of some of
the blockbuster drugs (with annual sales of more than USD 5 billion) that are
being extensively administered via prefilled syringes.
In
addition, over 50 drugs are being developed in combination with prefilled
syringes. Majority (51%) of these combination products are used for delivery of
antibody therapeutics, followed by protein therapeutics. Presently, more than 60%
prefilled syringe combination products are under phase III of clinical
development, while 30% combination products are in phase II trials. It is worth
mentioning that around 45% combination products have been approved / being
developed for the treatment of autoimmune disorders and 19 vaccines have been
approved (in the last seven years) in combination of prefilled syringes for
treating infectious diseases. Examples of the approved vaccines include (in
alphabetical order, no selection criteria) BEXSERO®, HEPLISAV-B™, Hexacima® /
Hexyon®, Nimenrix™, TRUMENBA® and VAXELIS™.
Presently, prefilled syringes are widely used to administer a variety of therapeutics, including vaccines, anticoagulants, anti-arthritic drugs and anti-anemic drugs. In addition, the use of prefilled diluent syringes and flush syringes is also increasing. It is worth highlighting that maximum number of combination products (27) were approved in 2018. Further, majority (93) of the prefilled syringe combination products have been approved in the US, followed by Europe and Australia, where 68 and 29 combination products have been approved respectively.
Sponsor Ads
Created on Jul 6th 2020 06:29. Viewed 190 times.